CEO of Stada Group Visited Hemofarm

Shortly after easing of the security measures across the Stada Group, CEO Peter Goldschmidt visited Hemofarm's headquarters in Vršac. As he pointed out during the tour of the production facilities, the main reason of his visit was not business, but a desire to thank in person to all the employees who worked around the clock enabling the patients not to worry about their therapy even in the most challenging times. This visit was organized shortly after celebration of the 60th anniversary of Hemofarm and it was a chance for the company management to meet again with the employees and discuss the further plans.

Apart from meeting with the company management and visiting Hemofarm’s factory in Vršac, the leading man of Stada had a chance during this visit to talk to several leading editors and economic journalists in Serbia.

Generalni direktor Štada grupe posetio Hemofarm

Generalni direktor Štada grupe posetio Hemofarm

’The reason of my visit was not business, but I came to thank the employees in Serbia! They worked more than ever during the pandemic, and our production plants were not closed even for an hour. Serbs have demonstrated how efficient they are. Hemofarm is one of our biggest plants in terms of employee number, as well as our most important manufacturing site. On this occasion, I wanted to express my gratitude on behalf of other countries, because due to the great work of the Serbian company, also patients in Germany, Russia and other countries received medicines on time’, was the answer of the CEO of Stada when asked by the Serbian journalists about the reason of his visit to Serbia.

Asked whether companies in Europe will be under pressure of their governments to bring back the production to their countries since coronavirus demonstrated that there were problems in the supply chain especially when suppliers from other continents were concerned, Goldschmidt answered that such types of requests were to be expected, but they were not realistic or enforceable. ’Hemofarm is a good example how everything can function well, although the company is based outside Germany. The factory from Vršac produces medicines of the highest European quality, they are intended to patients from all around the world and it proved even during the present crisis that the regular supply was possible to meet.’

Asked whether, despite the current crisis caused by the pandemic, Stada will continue the planned investment in Hemofarm, Goldschmidt answered in the affirmative. During the one-hour talks with the journalists, the CEO of Stada answered also the questions about the consequences of the pandemic to the global pharmaceutical industry, whether Europe and Germany will face the recession which can influence also the business operations of Stada, about significance of the discovery of a vaccine against the coronavirus etc.